Core Viewpoint - A class action has been filed against Charming Medical, Limited (NASDAQ: MCTA) for alleged fraudulent stock promotion activities that misled investors and artificially inflated the company's stock price [1][2]. Allegations - The complaint alleges that Charming Medical was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [2]. - Insiders and affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures failed to mention the false rumors and artificial trading activity that were driving the stock price [2]. Stock Price Movement - In the weeks leading up to November 12, 2025, Charming's share price increased from the initial public offering price of $4.00 to a peak of $29.36 per share, despite a lack of fundamental news justifying such a rise [3]. - Investigations revealed that the stock was subject to an illicit promotion scheme that created a buying frenzy among retail investors through sensational claims made by impersonators on social media [3]. - Trading of Charming's stock was halted by the SEC on November 12, 2025, and remains suspended due to the company's failure to provide required information to regulators [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by February 17, 2026 [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [5].
Shareholder Rights Law Firm Robbins LLP Urges MCTA Investors to Contact the Firm About Their Rights Against Charming Medical, Limited